• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

马来西亚卫生部发起全国性C型肝炎检验活动

Home > Press Releases Translations

马来西亚卫生部发起全国性C型肝炎检验活动

One of the clinical volunteers from Hospital Tengku Ampuan Afzan (HTAA) preparing to screen a woman for hepatitis C
One of the clinical volunteers from Hospital Tengku Ampuan Afzan (HTAA) preparing to screen a woman for hepatitis C
17 Jul 2019
  • 中文
    • 中文
    • English
    • Malay
    • ไทย

(吉隆坡17日讯)

在“被忽视疾病药物研发倡议组织”(DNDi)和创新诊断基金会(FIND)的支持下,该活动在为这种无声但可治愈的疾病寻找“遗漏的数百万人”

创新诊断基金会(FIND)和被忽视疾病药物倡议组织(DNDi)正与马来西亚卫生部(MOH)合作,推出我国有史以来规模最大的C型肝炎病毒筛查计划。

“大马遗漏的万人”(#MYmissingmillions)活动早于2019年世界肝炎日来临之前公布,旨在提高人们对C型肝炎病毒早期诊断的重要性的意识,并确保所有国人都有机会免费接受检测及接受高效治疗。据估计,马来西亚约有40万人患有C型肝炎;而全球则有超过7100万人长期感染,其中80%以上的患者来自低收入和中等收入国家。这是一种无声的流行病,因为绝大多数的感染者并不知道自己身体的状况,也没有表现出疾病的症状,因此不寻求治疗。

该合作计划于7月份在全国14个州的100多家医院、初级医疗中心和FIND研究中心进行简单的快速诊断测试,为所有马来西亚人,特别是那些被认为具有高风险的人提供免费的筛查机会。所有确诊带有活跃的C型肝炎病毒(病毒血症)的患者将与当地政府的医疗机构连结起来,以得到护理,这些机构可提供直接作用的抗病毒治疗。

“大马遗漏的万人”活动是马来西亚卫生部在为C型肝炎进行简化与分散筛查及治疗方面所作出的更广泛努力的一部分。马来西亚国家C型肝炎计划采取更加全面的治疗策略,以克服国内C型肝炎治疗成本过高的问题,并在政府医院提供免费的C型肝炎治疗(索非布韦/达卡他韦,sofosbuvir/daclatasvir)。

DNDi和FIND希望他们的支持能够进一步推动政府寻找“大马遗漏的万人”的战略措施。

关于C型肝炎

C型肝炎是世界上最常见的传染病之一,一般通过不安全的医疗操作和注射吸毒传染。全球有超过7100万人患有慢性感染,其中80%以上生活在中低收入国家,但只有五分之一的人知道他们患有这种疾病。每年约有40万人死亡,死亡率也正在上升,使其成为全球卫生优先关注的问题:世界卫生组织(WHO)制定了2030年全面消灭病毒性肝炎的目标。在马来西亚,C型肝炎疾病负担很高,预计未来几十年将急剧上升,预计到2039年将有6万3900例C型肝炎相关死亡病例。欲了解更多信息,请浏览 www.dndi.org。

关于FIND

创新诊断基金会(Foundation for Innovative New Diagnostics, 简称FIND)是一个全球性的非营利组织,致力于开发和提供创新诊断技术,以对抗影响世界贫困人口的主要疾病。我们的工作与研发衔接,力图突破、克服技术发展的科学障碍;为监管者和决策者提供证据;解决市场失灵问题;促使中低收入国家加快获得和受到诊断。自2003年开始,我们在提供24种新型诊断工具的过程中发挥了重要作用。自2015年初,我们已向中低收入国家提供了超过5000万件获得 FIND 资助的产品。作为世界卫生组织合作中心,我们与全球 200 多个学术、工业、政府和民间团体合作伙伴合作,跨越 6 个重点疾病领域,开展 70 多个有效项目。FIND 致力于实现“治疗依托诊断”这样的一个未来,为疾病监测、控制和预防提供基础。欲了解更多信息,请浏览www.finddx.org。

关于 DNDi

“被忽视疾病药物研发倡议组织”(Drugs for Neglected Diseases initiative,简称DNDi)是一个非营利研发组织,致力为被忽视的病人提供新治疗法,尤其是针对昏睡病(非洲人类锥虫病)、南美锥虫病、利什曼病、淋巴丝虫病、足分枝菌病、儿科爱滋病毒/爱滋病以及C型肝炎病毒患者。DNDi的目标是通过研发和注册一种廉价、安全且有效的泛基因型直接作用的抗病毒药品(DAAs),以及通过支持政策改革和政治意愿来消除全球各国在取得该抗病毒药品上的障碍,让大众更容易获得C型肝炎病毒治疗。 www.dndi.org

媒体联系人

DNDi 东南亚: Molly Jagpal
+60 (0)12 546 8362
mjagpal@dndi.org

FIND: 传播负责人Sarah-Jane Loveday
+41 (0) 22 710 27 88
+41 (0) 79 431 62 44
media@finddx.org

Partnership Hepatitis C

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License